Nagasawa H T, Elberling J A, DeMaster E G, Shirota F N
Medical Research Laboratories, VA Medical Center, Minneapolis, Minnesota.
J Med Chem. 1989 Jun;32(6):1335-40. doi: 10.1021/jm00126a032.
On the basis of an earlier observation that the N1-ethyl derivative of the hypoglycemic agent chlorpropamide (CP) inhibited aldehyde dehydrogenase (AlDH) in rats without producing hypoglycemia, we undertook a structure-activity study to assess the effect of altering the alkyl substituents at N1 and N3, as well as substituting O for N at the latter position, and evaluated these analogues for their effect on AlDH in vivo and in vitro. Our results suggest that only those CP analogues that can release alkyl isocyanates nonenzymatically inhibited AlDH. Increasing the steric bulk of the N1-alkyl substituent enhanced isocyanate formation and AlDH inhibition. CP analogues that lacked the NH group at N3 or were otherwise incapable of alkyl isocyanate release were inactive.
基于早期的一项观察结果,即降血糖药物氯磺丙脲(CP)的N1-乙基衍生物在不引起低血糖的情况下抑制大鼠体内的醛脱氢酶(AlDH),我们进行了一项构效关系研究,以评估改变N1和N3位的烷基取代基以及在后者位置用O取代N的效果,并评估这些类似物在体内和体外对AlDH的影响。我们的结果表明,只有那些能够非酶促释放烷基异氰酸酯的CP类似物才能抑制AlDH。增加N1-烷基取代基的空间位阻会增强异氰酸酯的形成和对AlDH的抑制作用。在N3位缺乏NH基团或以其他方式无法释放烷基异氰酸酯的CP类似物没有活性。